Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Other financing activities: 2020-2023

Historic Other financing activities for Xeris Biopharma Holdings (XERS) over the last 1 years, with Dec 2023 value amounting to $1.2 million.

  • Xeris Biopharma Holdings' Other financing activities rose 1875.00% to $1.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was $1.7 million, marking a year-over-year decrease of 65.11%. This contributed to the annual value of $1.2 million for FY2023, which is 75.70% down from last year.
  • Per Xeris Biopharma Holdings' latest filing, its Other financing activities stood at $1.2 million for Q4 2023, which was up 1,875.00% from $60,000 recorded in Q4 2022.
  • Over the past 5 years, Xeris Biopharma Holdings' Other financing activities peaked at $4.4 million during Q1 2022, and registered a low of $54,000 during Q2 2021.
  • Moreover, its 3-year median value for Other financing activities was $228,000 (2022), whereas its average is $1.0 million.
  • Data for Xeris Biopharma Holdings' Other financing activities shows a peak YoY soared of 1,875.00% (in 2023) over the last 5 years.
  • Over the past 4 years, Xeris Biopharma Holdings' Other financing activities (Quarterly) stood at $57,000 in 2020, then reached $54,000 in 2021, then surged by 450.00% to $60,000 in 2022, then soared by 1,875.00% to $1.2 million in 2023.
  • Its Other financing activities was $1.2 million in Q4 2023, compared to $60,000 in Q4 2022 and $159,000 in Q3 2022.